Evidence for reduced 3 beta-ol-hydroxysteroid dehydrogenase activity in some hirsute women thought to have polycystic ovary syndrome - PubMed (original) (raw)

Evidence for reduced 3 beta-ol-hydroxysteroid dehydrogenase activity in some hirsute women thought to have polycystic ovary syndrome

R A Lobo et al. J Clin Endocrinol Metab. 1981 Aug.

Abstract

Congenital adrenal hyperplasia due to 3 beta-ol-hydroxysteroid dehydrogenase (3 beta-ol) deficiency is usually lethal. A partial deficiency in 3 beta-ol has been suggested in some women presenting with androgen excess. In this study, 24 women were investigated who had hirsutism and oligomenorrhea and high serum delta 5 androgens compared to delta 4 androgens. Of these women, 9 had significantly elevated 17-hydroxypregnenolone (17 Preg) to 17-hydroxyprogesterone (17 Prog) ratios when compared to controls under basal conditions. On further testing of 9 women with ACTH, 4 had significantly elevated 17 Preg to 17 Prog ratios. Eight women had elevated ratios of dehydroepiandrosterone sulfate to androstenedione, 4 had elevations of androstenediol (Adiol) to testosterone (T), and 4 had abnormal 17 Preg to cortisol ratios. Only 3 women out of the original 24 selected for study had elevated ratios for all 4 different steroid pairs measured. 17 Prog was normal in these women with 3 beta-ol deficiency in contradistinction to the high levels normally observed in women with congenital adrenal hyperplasia due to 21- or 11-hydroxylase deficiency. It is suggested that the cause of androgen excess in these women is high circulating levels of Adiol and, in part, the slightly elevated unbound T levels in these women. In conclusion, a subtle, incomplete form of 3 beta-ol deficiency may exist in adult women and is manifest by high delta 5 androgens such as dehydroepiandrosterone sulfate and Adiol and normal delta 4 androgens such as androstenedione and T.

PubMed Disclaimer

Cited by

Differential activity of the corticosteroidogenic enzymes in normal cycling women and women with polycystic ovary syndrome.
Yamamoto MMW, de Medeiros SF. Yamamoto MMW, et al. Rev Endocr Metab Disord. 2019 Mar;20(1):3-13. doi: 10.1007/s11154-019-09482-3. Rev Endocr Metab Disord. 2019. PMID: 30798426 Review.
Metabolic and endocrine connections of 17-hydroxypregnenolone in polycystic ovary syndrome women.
de Medeiros SF, Ormond CM, de Medeiros MAS, de Souza Santos N, Banhara CR, Yamamoto MMW. de Medeiros SF, et al. Endocr Connect. 2017 Oct;6(7):479-488. doi: 10.1530/EC-17-0151. Epub 2017 Aug 7. Endocr Connect. 2017. PMID: 28784626 Free PMC article.
The next 150 years of congenital adrenal hyperplasia.
Turcu AF, Auchus RJ. Turcu AF, et al. J Steroid Biochem Mol Biol. 2015 Sep;153:63-71. doi: 10.1016/j.jsbmb.2015.05.013. Epub 2015 Jun 3. J Steroid Biochem Mol Biol. 2015. PMID: 26047556 Free PMC article. Review.
Adrenal hyperandrogenism in the pathophysiology of polycystic ovary syndrome.
Carmina E, Lobo RA. Carmina E, et al. J Endocrinol Invest. 1998 Oct;21(9):580-8. doi: 10.1007/BF03350783. J Endocrinol Invest. 1998. PMID: 9856412 Review. No abstract available.
Pituitary and adrenal response to ovine corticotropin-releasing hormone in women with polycystic ovarian syndrome.
Mongioì A, Macchi M, Vicari E, Fornito MC, Calogero AE, Riccioli C, Minacapilli G, Moncada ML, D'Agata R. Mongioì A, et al. J Endocrinol Invest. 1988 Oct;11(9):637-40. doi: 10.1007/BF03350202. J Endocrinol Invest. 1988. PMID: 3265424

Evidence for reduced 3 beta-ol-hydroxysteroid dehydrogenase activity in some hirsute women thought to have polycystic ovary syndrome - PubMed (original) (raw)